Superior Court of Justice – Ontario has fully dismissed the statement of the claim issued by Apollo Technology Capital Corporation, Nobul Technologies, and Regan McGee on May 5, 2025, against MediPharm's Chief Executive Officer, David Pidduck, and Chairman of the Board, Chris Taves.
Further to the Company's press release dated May 28, 2025, in which the Company announced that the Plaintiffs agreed to dismiss the frivolous $50 million conflict of interest claim against the Company's litigation counsel, in its entirety on a with-prejudice basis, MediPharm is pleased to announce that the Court has now granted the anti-SLAPP motion brought by Mr. Pidduck and Mr. Taves under the "anti-SLAPP" provisions of section 137.1(3) of the Courts of Justice Act (Ontario), dismissing the remaining libel allegations against them in full.
The Plaintiffs sought, amongst other things, damages in the amount of $50 million against Mr. Pidduck and Mr. Taves for defamation relating to a letter that was sent to a former executive of a MediPharm subsidiary working alongside Apollo on April 29, 2025 in connection with the proxy contest initiated by the Plaintiffs. In making its decision to grant the Motion, and dismiss all remaining aspects of the Claim in full.
For more information:
MediPharm Labs
medipharmlabs.com
